BAX
Baxter International Inc Health Care Surgical & Medical Instruments & Apparatus S&P 500Russell 3000
$23.00Close
$15.7BMarket cap
$15.79 – $28.3452-week range
Late-januaryNext report · estimated
Highlights
Cautions
- Trend not confirmed 6 of 8 conditions · under the 50-day, RS under 70
- Lagging the market RS 49 · weaker than 51% of stocks over 12 months
- Distribution down-day volume 1.8× up-day volume over 50 sessions
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
19%
1wk
down 9.1%
price change
1mo
down 4.2%
price change
12-month return
up 20%
market up 11% ·
its own down 8%
F-score
6 / 9
Mixed
Altman Z
2.38
Moderate risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.6×
price / book
Earnings yield
down 1.3%
EBIT / enterprise value
Cheaper than
40%
of the market · expensive
Revenue growth
up 6%
year on year
EPS growth
—
latest quarter
Sales growth
up 5%
latest quarter · -0 pts
ROE
down 15%
return on equity
Free cash margin
up 3%
$332.0M FCF
D/E
1.55
long-term debt / equity
Net debt / EBITDA
11.2×
Interest cover
Lossoperating loss
Piotroski tests
- not yet profitable on its assets
- profitability slipped from last year
- gross margin narrowed
- generating cash from operations
- profits backed by cash
- reduced long-term debt
- short-term liquidity improved
- no new shares issued
- assets working harder
Repair signals
- Long-term debt down 28% ($13.1B → $9.5B)
Trade setup
ATR%
3.9%
$0.91 a day · 2×ATR $21.19
RS
49 / 99
vs the universe
Trend
6 / 8
under the 50-day, RS under 70
Relative volume
1.9×
vs 50-day average
Up/down volume
0.57
50 sessions
Implied move
—
no scheduled report
Trend template · 6 of 8
- Price above the 50-day average: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Heavily indebted Net debt is 11.2 times EBITDA — roughly 11 years of earnings before interest, tax and depreciation to repay borrowings in full.
- Gross margin narrowing Gross margin fell from 37.5% to 30.1%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Oct 29, 2026
Results reaction
Oct 29, 2026-8% vs market2 sessions after results
Options
$280,90036.0% IV · activity
Financials
- Gross 30%
- Net -9%
- Free cash 3%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $11.7B | $12.1B | $10.1B | $10.4B | $10.6B | $11.2B |
| Gross margin | 39% | 39% | 35% | 40% | 37% | 30% |
| Operating income | $1.6B | $1.4B | -$2.8B | $707.0M | $14.0M | -$308.0M |
| Net income | $1.1B | $1.3B | -$2.4B | $2.7B | -$649.0M | -$957.0M |
| Net margin | 9% | 11% | -24% | 26% | -6% | -9% |
| Earnings per share | $2.13 | $2.53 | -$4.83 | $5.23 | -$1.27 | -$1.87 |
| Free cash flow | $1.2B | $1.5B | $834.0M | $1.3B | $573.0M | $332.0M |
| Free cash margin | 10% | 13% | 8% | 12% | 5% | 3% |
| Cash | $3.7B | $3.0B | $1.6B | $3.1B | $1.8B | $2.0B |
| Long-term debt | $6.2B | $17.7B | $16.6B | $13.8B | $13.1B | $9.5B |
| Shareholders' equity | $8.7B | $9.1B | $5.8B | $8.4B | $7.0B | $6.1B |
| Shares outstanding | 683.49m | 683.49m | 683.49m | 683.49m | 683.49m | 683.49m |
What options price now
- Expected 1-month range The at-the-money straddle for the expiry nearest a month out, as a share of the price: the move, either way, the option market is pricing by then. The range is the price plus and minus that move; the stock ends inside it a little more often than not. Methodology
- $21 – $25 ±7.9% by Nov 27, 2026
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Smaller 36.0% priced · 42.2% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- Choppier
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs more
Positioning
- Premium traded
- $280,900 calls $188,038 · puts $92,862 · latest session
- 0.49× +0.45 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls +1.47k · puts +277 past week
For options traders: ATM IV 36.0% (-15.7% 1w) · 1m ÷ 3m IV 1.14 · 25Δ skew 2.6 pts · Net GEX $726,949
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 29, 2026 | Quarterly ↗ | Sep 30, 2026 | 29d |
| Jul 30, 2026 | Quarterly ↗ | Jun 30, 2026 | 30d |
| Apr 30, 2026 | Quarterly ↗ | Mar 31, 2026 | 30d |
| Feb 12, 2026 | Annual ↗ | Dec 31, 2025 | 43d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 21, 2025 | Annual ↗ | Dec 31, 2024 | 52d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 8, 2024 | Annual ↗ | Dec 31, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Results · Other events ↗ |
| Aug 19, 2026 | Director or officer change · Regulation FD ↗ |
| Aug 18, 2026 | Material agreement · Other events ↗ |
| Aug 4, 2026 | Other events ↗ |
| Aug 4, 2026 | Director or officer change ↗ |
| Jul 30, 2026 | Results · Other events ↗ |
| Jul 14, 2026 | Regulation FD ↗ |
| May 8, 2026 | Director or officer change · Charter or bylaws · Shareholder vote ↗ |
| Apr 30, 2026 | Results · Other events ↗ |
| Mar 19, 2026 | Regulation FD ↗ |
| Mar 16, 2026 | Director or officer change · Regulation FD ↗ |
| Feb 12, 2026 | Results · Director or officer change · Other events ↗ |